Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Portfolio Pulse from Benzinga Newsdesk
Cullinan Therapeutics announced initial data from its Phase 2b REZILIENT1 study of Zipalertinib, showing similar anti-tumor activity in 18 evaluable patients compared to prior chemotherapy results.

June 03, 2024 | 8:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cullinan Therapeutics announced initial data from its Phase 2b REZILIENT1 study of Zipalertinib, showing similar anti-tumor activity in 18 evaluable patients compared to prior chemotherapy results.
The announcement of promising initial data from the Phase 2b study of Zipalertinib is likely to positively impact Cullinan Therapeutics' stock price in the short term. The data shows consistent anti-tumor activity, which is a positive indicator for the drug's efficacy and potential future approval.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100